The self-administered COVID-19 sample collection kit integrates comprehensive telehealth support with the ease and convenience of at-home saliva collection.
ATLANTA, June 2, 2020 – BioIQ, a healthcare engagement and clinical adherence technology platform company, announces the availability of an at-home RT-PCR COVID-19 testing solution with fully integrated telehealth support. The test is being offered in partnership with P23 Labs, one of the first laboratories to receive Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for home saliva collection in conjunction with telehealth oversight. The partnership enables BioIQ to connect employees, health plan members, and individuals with COVID-19 diagnostic testing under the virtual supervision of a clinician.
The test sample collection kit includes an easy-to-use, self-administered saliva collection kit and virtual telehealth guidance, along with access to a health technology platform to support digital symptom and exposure assessment, contact tracing, and follow-up care navigation. Test results are delivered within 24-48 hours of receipt of lab sample.
The new at-home testing solution is the latest addition to BioIQ’s end-to-end COVID-19 testing and return-to-work platform. The testing ecosystem includes RT-PCR SARS-CoV-2 diagnostic and IgM/IgG antibody test kits; a technology platform to support assessment and contact tracing, population analytics, results monitoring, and communications; regional physical and national telehealth-enabled providers to support clinical oversight; and strategic and legal resources to offer employers step-by-step guidance on how to safely and confidently reopen for business. Diagnostic testing is a critical component to a broader technology-based solution for population communication, testing, disease mitigation, and monitoring in order to effectively manage disease risk.
“The combination of easy home saliva collection along with integrated telehealth presents a significant step forward for the diagnostic testing of COVID-19,” said BioIQ CEO Justin Bellante. “This will take participant experience, comfort, and confidence to the next level as the nation pushes to increase testing capacity.”
“P23 Labs is enthusiastic to work with BioIQ to increase COVID-related testing access in the US,” said P23 Labs Sr. Regulatory Officer Mary Smith. “Our at-home kit elevates saliva-based COVID-19 testing standards with a highly accurate test that marries convenience with remote clinician oversight. This not only assists with sample collection, but also improves peace of mind throughout the entire testing and results process.”
The new at-home testing solution will be available as part of BioIQ’s back-to-work COVID-19 testing solution for employers. In addition, BioIQ continues to target healthcare workers, essential workforce, and vulnerable patient populations as top testing priorities – all in support of the testing needs of employers, health plans, and government agencies.
Organizations seeking assistance with COVID-19 testing initiatives can contact BioIQ at 888-818-1594 or visit https://www.bioiq.com/covid-19-solution/.
BioIQ is a healthcare engagement and clinical adherence technology platform company that is redefining the way payers, employers and consumers navigate and connect with the US healthcare system. BioIQ leverages consumer analytics, real-time program intelligence, omnichannel personalized engagement strategies and an extensive ecosystem of healthcare partners to provide a comprehensive view of individuals throughout their health journey and engage them to get testing and care that leads to healthier outcomes.
With more than a decade of healthcare industry experience and a first-of-its-kind health connectivity platform, BioIQ is uniquely positioned at the convergence of population health and the consumerization and retailization of healthcare to drive the shift to value-based care for payers and employers. Since 2005, BioIQ has launched thousands of successful health testing programs serving millions of participants. For more information, visit www.bioiq.com.
About P23 Labs
P23 Labs is a high-complexity molecular diagnostics laboratory that specializes in preventative diagnostic testing of infectious disease. P23 Labs offer a full suite of molecular diagnostic tests that also include COVID-19, respiratory pathogen profiles, and other infectious diseases rapidly identified via our state-of-the-art molecular methods. Our emphasis is on women’s health and serving the underserved communities in the United States. P23 Labs is dedicated to removing healthcare barriers and improving healthcare literacy.
Founded in 2020, P23 captured on the unique opportunity for a quality laboratory that focuses on fortifying the relationship of patients and providers by increasing access to healthcare. P23 Labs staff have a combined 150 plus years of experience in genetics, epidemiology, business, finance, and clinical medical practice. P23 Labs combine innovation, quality, and creativity with science to emerge as a leader in molecular testing. P23 Labs is headquartered in Little Rock, AR. For more information visit www.p23labs.com.
Chief Marketing Officer